



ANYLIN PHARMACEUTICALS

**UNITED STATES DEPARTMENT OF COMMERCE**  
**Patent and Trademark Office**

 Address: COMMISSIONER OF PATENTS AND TRADEMARKS  
 Washington, D.C. 20231

SERIAL NUMBER	FILING DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NO.
08/870,762	6.6.97	Dufl et al.	926/104
08/870,762	06/06/97	DUFT	2267104

 BRADFORD J. DUFT ESQ.  
 BROBECK, PHLEGER AND HARRISON LLP.  
 9373 TOWNE CENTER DRIVE  
 SAN DIEGO CA 92121

HM12/0525

EXAMINER	
S. Devi	
ARTICLE, S	PAPER NUMBER
1645	

DATE MAILED 845

**NOTICE OF ABANDONMENT**

05/25/01

This application is abandoned in view of:

- ☒ Applicant's failure to respond to the Office letter, mailed 11-13-2000.
- ☐ Applicant's letter of express abandonment which is in compliance with 37 C.F.R. 1.138.
- ☐ Applicant's failure to timely file the response received \_\_\_\_\_ within the period set in the Office letter.
- ☐ Applicant's failure to pay the required issue fee within the statutory period of 3 months from the mailing date of \_\_\_\_\_ of the Notice of Allowance.
  - ☐ The issue fee was received on \_\_\_\_\_
  - ☐ The issue fee has not been received in Allowed Files Branch as of \_\_\_\_\_

In accordance with 35 U.S.C. 151, and under the provisions of 37 C.F.R. 1.316(b), applicant(s) may petition the Commissioner to accept the delayed payment of the issue fee if the delay in payment was unavoidable. The petition must be accompanied by the issue fee, unless it has been previously submitted, in the amount specified by 37 C.F.R. 1.17(l), and a verified showing as to the causes of the delay.

If applicant(s) never received the Notice of Allowance, a petition for a new Notice of Allowance and withdrawal of the holding of abandonment may be appropriate in view of *Delgar Inc. v. Schuyler*, 172 U.S.P.Q. 513.
- ☐ Applicant's failure to timely correct the drawings and/or submit new or substitute formal drawings by \_\_\_\_\_ as required in the last Office action.
  - ☐ The corrected and/or substitute drawings were received on \_\_\_\_\_
- ☐ The reason(s) below.

**RECEIVED**

MAY 29 2001

 ANYLIN PHARMACEUTICALS, INC.  
 LEGAL DEPARTMENT

 SD/  
 S. Devi  
 Patent Examiner  
 May 01.

 RECEIVED  
 APR 20 2005  
 TECH CENTER 1600/2900